Prescribing Information LYNPARZA (olaparib) United Kingdom

This website is intended for UK Healthcare Professionals only. Other UK residents please visit astrazeneca.co.uk

Expert-led webinars by the Prostate Cancer Academy

Learn from the experts and join your peers in the discussion of key topics and best practice in advanced prostate cancer care in our four-part webinar series, brought to you by the Prostate Cancer Academy. These webinars are live events with on-demand material uploaded to this page as they become available.

Mastering Clinical Paper Statistics

Professor Gareth Griffiths explores the PROpel study data to highlight key considerations when interpreting statistics in clinical trials, and how to apply these findings to clinical practice.

WATCH NOW

Cardiovascular Risks and Co-morbidities

Consultant Cardiologist Dr Alexander Lyon shares valuable insights into identifying and managing cardiovascular adverse events in patients with mCRPC, providing practical guidance to enhance clinical decision-making and confidence in managing such events.

WATCH NOW

The Role of PSMA/PET Scans

Consultant Clinical Oncologist Dr Tom Bird discusses PSMA/PET imaging and it's accuracy over conventional methods for staging and managing prostate cancer and how it could enable more personalised treatment decisions and improved detection of metastatic disease.

WATCH NOW

Psychosexual Management

Psychosexual Nurse Lorraine Grover discussed the integration of psychosexual support into the care of patients with mCRPC to help them achieve individual sexual wellbeing related goals.

WATCH NOW

Want to learn more about LYNPARZA?

1L=first-line; mCRPC=metastatic castration-resistant prostate cancer; PET=positron emission tomography; PSMA=prostate-specific membrane antigen.

LYNPARZA (olaparib). Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/9204/smpc Accessed January 2026.

GB-70881 | DOP: February 2026

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling ‌‌‌0‌‌‌8‌‌‌‌‌0‌‌‌‌0‌‌‌ ‌‌7‌‌‌‌‌‌8‌‌‌3‌‌‌ ‌‌0‌‌‌‌‌0‌‌‌‌3‌‌‌‌3‌‌‌.

This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.

Cookie Policy

Expert-led webinars by the Prostate Cancer Academy

Want to learn more about LYNPARZA?

Abbreviations and References

These Lynparza website pages were funded and produced by AstraZeneca UK and MSD UK.

Enhance your knowledge, stay informed

Be the first to know. Hear about events, products and ways to support your patients.

Thank you. We will be in touch